Three-year efficacy of switching to dolutegravir plus lamivudine: A real-world study.
Palmier E, De Miguel R, Montejano R, Busca C, Micán R, Ramos L, Cadiñanos J, Serrano L, Bernardino JI, Pérez-Valero I, Valencia E, Arribas JR, Montes ML, González-García J, Martín-Carbonero L.
Palmier E, et al.
HIV Med. 2023 Sep;24(9):1013-1019. doi: 10.1111/hiv.13500. Epub 2023 May 16.
HIV Med. 2023.
PMID: 37194419